Unlocking Hope for Cancer Patients Using PDT
TARGET INDICATIONS AND TIMEFRAMES
MULTIPLE CLINICAL TRIALS, MULTIPLE INDICATIONS AND FORMULATIONS
10
DISEASE AREA (CALENDAR YEAR)
2H2023
1H2024
2H2024
1H2025
2H2025
>CY26
CANCER1
Non-Melanoma Skin Cancers (Topical)²
Solid Tumour Cancer Indication (IV): (TBC)
Anogenital Cancers (Topical)
Additional Indications: International (TBC)
NEXT CLINICAL TARGET INFECTIOUS DISEASES
Oral Microbial (Peri-Implant Mucositis)³
HPV (Dr.inB)
Discovery
PreClinical
Recruitment and Treatment
Adaptive study design
Follow up and monitoring
Phase 1
Phase 1b/2
1 RMW Cho Group ("RMW") as licensor of PhotosoftTM technology, is pursuing independent research in parallel with Invion's R&D efforts including a prostate
cancer trial. The research is complementary/supplemental to Invion's development program. To the extent that Invion becomes aware of material
information relating to RMW's studies, Invion will release the information to the ASX in compliance with its disclosure obligations (noting however that Invion
is not involved in RMW's studies and does not have direct access to information)
2 NMSC trial uses an adaptive study design means recruitment numbers and timelines may change to accelerate the evaluation of INV043
3 Timing subject to ongoing dialog with US FDA to determine pre-clinical requirements
INVIONView entire presentation